Immune Globulin Articles
This common virus manifests in a host of systemic illnesses that are mostly curable with human intravenous immune globulin therapy.
A potential solution for CIDP patients with these IVIG-related issues is self-administered subcutaneous immune globulin.
Researchers are taking a closer look at intravenous immune globulin for its potential to stop the progression of multiple complex conditions from lupus to multiple sclerosis.
The U.S. market for IVIG continues to grow well over 5 percent annually. What is driving the market demand?
The plasma donor is the first vital part of the process to produce safe and effective plasma protein therapeutics, and the industry prioritizes the safety and health of its plasma donors.
